When He Xiaojun said this, Xiao Feng suddenly slapped his hands.

"Now you finally understand!"

In fact, as I said before, middle- and high-level scientific researchers in those companies will leave the company after reaching a certain age or achieving certain results.

Xiao Feng was constantly thinking about how to arrange these personnel.

In fact, this is a dilemma.

Why do those major Internet companies try their best to let their employees return to society when they reach the age of thirty-five?

The explanation given by those large companies is that at this age, if these employees have not reached the position of middle managers or project leaders, it means there is a problem with their abilities.

And at this age, the creativity of these programmers has almost reached its limit, and it is difficult to make other breakthroughs.

Although this may sound uncomfortable, it is the bloody reality.

For those programmers, they really did nothing wrong. They have dedicated more than ten years to the company, but at this age, the company wants them to return to society, which is really difficult.

Moreover, at this age, it is very difficult to find other jobs.

Fortunately, they have experience working in a large factory, which may help them find other jobs.

Fortunately, the company has never treated them badly over the years, at least in terms of salary.

As for those big manufacturers, they actually don't want to bear the reputation of being a waste of time and money.

But there is no way, why don't we have the support of wealthy consortiums like those in Europe and the United States?

For example, Google and Apple may not let older, uncreative employees leave because they can afford them.

Because first of all, they have accumulated a lot of technology patents. Each company can only rely on those hundreds of thousands of patents to collect patent fees every year.

In addition, because they are the leading company in the industry and have the background of the world's strongest G, this allows them to enter and exit any market in the world unimpeded.

Therefore, it must be much easier for them to make money than our domestic companies.

And we are on the road to catch up now, so we definitely don’t dare to be as luxurious as them.

The same principle applies to the researchers of Laboratory 9.

When their internal R&D personnel reach a certain age, their thinking has been basically finalized, and their creativity is basically close to zero.

The company definitely cannot keep these people for a long time because of their salary? They must be at a high level in the company's internal salary structure.

At the same time, the company recruits a group of capable fresh blood every year.

And most of these new blood are graduates from prestigious schools? When recruiting such people, they must be given sufficient salary.

Adding up both sides, these high salaries and benefits will inevitably greatly increase the company's operating costs.

But if you let those old employees resign in such a simple and crude way, you also have to worry about them being poached by foreign companies and leaking the company's technical secrets.

On the other hand, it is also a waste of talents.

So how to solve this problem?

Xiao Feng’s proposal gives the answer? Support a technology industry alliance.

These old employees have served the company for a long time and must have a deep understanding of certain details of the company.

For example, they know certain materials and equipment best.

What if a fund was set up to specifically support them in starting their own businesses?

What details does the company not have the experience to take care of? They can do it.

Once you do something well, you can help the company in turn.

And these people have been working in the company for such a long time? They must know the biggest needs of employees in various positions in the company best.

What if they developed something based on the needs of employees in each department? It would definitely improve the company's office efficiency, right?

In addition, the company will recently implement 3M's management methods internally.

Give R&D personnel 15% every week? Or even one day? Let them develop things that interest them.

And what these people develop? A considerable number of them may not succeed, but about 30% may bear fruit.

Among these achievements, some people who like to engage in R&D may enjoy their R&D achievements with the company.

For such R&D personnel, the company will naturally not hesitate to reward them, not to mention promotions and salary increases.

They will also share patents with him and sign a special contract with him. Even if the company's products are not sold, he will get a fixed proportion of the product.

But there are also other ambitious employees who may not like this result.

They may prefer to go out and start their own business on their own.

But if you go out to work alone, you will inevitably take certain risks, or you may need start-up capital.

At this time, the company's newly established fund will review their ideas.

For valuable projects, the company will naturally not hesitate to invest and become the major shareholder of the project.

By then, if this new venture is completed, it will be listed on the Science and Technology Innovation Board in the future.

That company would make a lot of money!

And the more such companies there are, the more beneficial it will be for Laboratory 9.

In the future, the company will gain a good reputation as a technology industry incubator, and more and more large companies will start from Lab 9.

This is also a huge honor for the company.

As for employees who want to leave the company and start their own businesses, Xiao Feng's attitude is very open. He not only welcomes them, but also provides strong support.

Because once they leave, positions will be vacant, which is more conducive to the metabolism within the company and gives new people the opportunity to take up positions.

On the other hand, if they can succeed, it will also mean a huge return on the company's investment.

And when Xiao Feng and He Xiaojun explained this, Xiao Feng finally understood what Xiao Feng had said before about social honor and sense of responsibility.

Indeed, if Lab 9 really supports such companies, even if there are only one or two, then their status in the circle will be unquestionable.

Before long, he will be the absolute leader of the martial arts industry!

Think about Penguin and a certain group, etc. There are countless such examples in the Internet industry.

In the real industry, there are countless such examples.

For example, Foxconn around Apple, as well as Bourne Optical, Ruisheng Technology, etc.

That hasn't spread to the upstream and downstream of the entire industry.

What Xiao Feng means now is to become the core leader of the entire industry chain.

Grasp the big and let go of the small, do the core part yourself, and then let others do the upstream and downstream work.

In fact, as their ninth laboratory has developed to this day, there are still countless companies in the upstream and downstream.

But the difference between them and Apple is that Apple has never been able to support a certain company.

What Lab 9 needs to do now is that Xiao Feng plans to set up a fund to specifically select some companies from upstream and downstream and support them.

In recent years, with the vigorous development of the Ninth Laboratory, hundreds of upstream and downstream companies, large and small, have been born in the development zone north of Bincheng, specializing in supporting them.

To be honest, the technical level of these enterprises is not very high.

Some of these companies produce outer packaging for their drugs, and some produce some equipment and consumables specifically used by the Ninth Laboratory.

Anyway, there are hundreds of these companies, large and small.

Now they have a dedicated person in charge every day, staying at the headquarters of the Ninth Laboratory on Daxing Island.

Once there is any procurement from the Ninth Laboratory, they will immediately contact the people in the purchasing department and then bid based on their qualifications and the contents of the bidding.

Now Xiao Feng plans to set up a business promotion fund to support these enterprises.

In fact, on the surface, these companies seem to have low technical levels.

But in fact, if they really work hard in their own field, their industry will still be very promising.

For example, those seemingly simple small glass bottles for storing medicines and light-blocking plastic paper will be very interesting if you study them carefully.

Even if it is a small needle for injection, as long as you study it carefully, you will find the technological gap between us and foreign countries.

For example, we often see the multi-functional operating beds and hospital beds that push patients in major hospitals.

This thing seems very simple, but in fact we import most of it from Japan.

As for why? There is no other reason. Their technology is good and their products are durable.

Needless to say, as for other medical equipment, as long as there are some medical equipment with technical content used in many hospitals, most of them are imported.

What Xiao Feng wants to do is to support his small upstream and downstream factories and participate in competition in this area.

He not only wants to support those R&D personnel who have ideas and want to start a business out of the company.

He also needs to support the company's upstream and downstream enterprises.

As long as medical equipment is involved, he intends to support these companies in industrial upgrading, but he will research more equipment that is currently in short supply in domestic hospitals and the medical market.

Those who don't have enough money can get support from the Quanye Fund he is about to establish.

Even technically, we can get support from him.

Anyway, he still has dozens of cloning experts here. These experts may not be of much help to the development of modern medicine.

But for future updates and iterations of medical equipment, these cloning experts can still play a role.

As for medicine, given the current capabilities of domestic pharmaceutical companies, it is estimated that they will not do much in the short term.
Chapter completed!